The present invention provides a Lactococcus lactis subspecies lactis isolate WFLU-12 with the accession number o KCTC 13180BP, and a use thereof.

Described is a method for the generation of a live vaccine containing stable bacteria carrying at least three attenuating mutations and a vaccine containing bacteria obtained by said method.

The present invention provides novel, recombinant Gram-negative bacteria. In particular, the invention provides recombinant Gram-negative bacteria (e.g., E. coli) lacking genes involved in lipopolysaccharide (LPS, endotoxin) biosynthesis (e.g., lacking genes required for core oligosaccharide biosynthesis) and also provides recombinant Gram-negative bacteria lacking genes involved in LPS biosynthesis that contain one or more exogenous KDO transferases and/or one or more exogenous heptosyltransferases (e.g., from one or more types and/or strains of bacteria). The invention further provides methods of generating and utilizing (e.g., as or in an immunogenic composition (e.g., as or in an adjuvant and/or vaccine)) the recombinant Gram-negative bacteria therapeutic, preventative, and/or research applications.

Described is a method for the generation of a live vaccine containing stable bacteria carrying at least three attenuating mutations and a vaccine containing bacteria obtained by said method.

The present invention provides a Lactococcus lactis subspecies lactis isolate WFLU-12 with the accession number of KCTC 13180BP, and a use thereof.

The present invention provides novel, recombinant Gram-negative bacteria. In particular, the invention provides recombinant Gram-negative bacteria (e.g., E. coli) lacking genes involved in lipopolysaccharide (LPS, endotoxin) biosynthesis (e.g., lacking genes required for core oligosaccharide biosynthesis) and also provides recombinant Gram-negative bacteria lacking genes involved in LPS biosynthesis that contain one or more exogenous KDO transferases and/or one or more exogenous heptosyltransferases (e.g., from one or more types and/or strains of bacteria). The invention further provides methods of generating and utilizing (e.g., as or in an immunogenic composition (e.g., as or in an adjuvant and/or vaccine)) the recombinant Gram-negative bacteria therapeutic, preventative, and/or research applications.

Described is a method for the generation of a live vaccine containing stable bacteria carrying at least three attenuating mutations and a vaccine containing bacteria obtained by said method.

The present invention provides a Lactococcus lactis subspecies lactis isolate WFLU-12 with the accession number o KCTC 13180BP, and a use thereof.

Described is a method for the generation of a live vaccine containing stable bacteria carrying at least three attenuating mutations and a vaccine containing bacteria obtained by said method.

The present application provides a vaccine composition comprising: bacteria engineered to express at least one N-glycan of Campylobacter, such as C. jejuni for example, or an N-glycan derivative thereof on its cell surface; and one or more of a physiologically acceptable diluent, excipient, adjuvant or carrier. The bacteria is Escherichia coli, Salmonella or any suitable bacteria that offers sufficient expression and improved immunogenic response. The vaccine composition can be formulated for administration to animals, such as poultry, including chickens.